🎉 M&A multiples are live!
Check it out!

Cynata Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Cynata Therapeutics and similar public comparables like Mesoblast, Aroa Biosurgery, and Orthocell.

Cynata Therapeutics Overview

About Cynata Therapeutics

Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.


Founded

2003

HQ

Australia
Employees

2

Website

cynata.com

Financials

LTM Revenue $0.9M

LTM EBITDA n/a

EV

$24.8M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Cynata Therapeutics Financials

Cynata Therapeutics has a last 12-month revenue of $0.9M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Cynata Therapeutics achieved revenue of n/a and an EBITDA of -$7.8M.

Cynata Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Cynata Therapeutics valuation multiples based on analyst estimates

Cynata Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$10.3M -$7.8M XXX XXX XXX
EBITDA Margin NaN% NaN% XXX XXX XXX
Net Profit -$3.4M -$9.0M XXX XXX XXX
Net Margin NaN% NaN% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Cynata Therapeutics Stock Performance

As of March 14, 2025, Cynata Therapeutics's stock price is AUD 0 (or $0).

Cynata Therapeutics has current market cap of AUD 49.7M (or $31.4M), and EV of AUD 39.2M (or $24.8M).

See Cynata Therapeutics trading valuation data

Cynata Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$24.8M $31.4M XXX XXX XXX XXX $-0.03

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Cynata Therapeutics Valuation Multiples

As of March 14, 2025, Cynata Therapeutics has market cap of $31.4M and EV of $24.8M.

Cynata Therapeutics's trades at 28.1x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Cynata Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Cynata Therapeutics and 10K+ public comps

Cynata Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $24.8M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -4.0x XXX XXX XXX
P/E -5.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -4.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Cynata Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Cynata Therapeutics Valuation Multiples

Cynata Therapeutics's NTM/LTM revenue growth is 512%

Cynata Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $4.0M for the same period.

Over next 12 months, Cynata Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Cynata Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Cynata Therapeutics and other 10K+ public comps

Cynata Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -25% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $4.0M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Cynata Therapeutics Public Comps

See public comps and valuation multiples for Regenerative Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Lineage Cell Therapeutics XXX XXX XXX XXX XXX XXX
Arovella Therapeutics XXX XXX XXX XXX XXX XXX
Aroa Biosurgery XXX XXX XXX XXX XXX XXX
Mesoblast XXX XXX XXX XXX XXX XXX
Orthocell XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Cynata Therapeutics M&A and Investment Activity

Cynata Therapeutics acquired  XXX companies to date.

Last acquisition by Cynata Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Cynata Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Cynata Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Cynata Therapeutics

When was Cynata Therapeutics founded? Cynata Therapeutics was founded in 2003.
Where is Cynata Therapeutics headquartered? Cynata Therapeutics is headquartered in Australia.
How many employees does Cynata Therapeutics have? As of today, Cynata Therapeutics has 2 employees.
Is Cynata Therapeutics publicy listed? Yes, Cynata Therapeutics is a public company listed on ASX.
What is the stock symbol of Cynata Therapeutics? Cynata Therapeutics trades under CYP ticker.
When did Cynata Therapeutics go public? Cynata Therapeutics went public in 2007.
Who are competitors of Cynata Therapeutics? Similar companies to Cynata Therapeutics include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Mesoblast.
What is the current market cap of Cynata Therapeutics? Cynata Therapeutics's current market cap is $31.4M
What is the current revenue of Cynata Therapeutics? Cynata Therapeutics's last 12-month revenue is $0.9M.
What is the current EV/Revenue multiple of Cynata Therapeutics? Current revenue multiple of Cynata Therapeutics is 28.1x.
Is Cynata Therapeutics profitable? Yes, Cynata Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.